| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| No Relationships to Disclose |
|
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: AstraZeneca |
| Recipient: You |
| Company: Amgen |
| Recipient: You |
| Company: Genentech |
| Recipient: You |
| Company: GlaxoSmithKline |
| Recipient: You |
| Company: Abbvie |
| Recipient: You |
| Company: Daiichi Sankyo/Astra Zeneca |
| Recipient: You |
| Company: Boehringer Ingelheim |
| Recipient: You |
| Company: EMD Serono |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: ArriVent Biopharma |
| Recipient: You |
| Company: Lilly |
| Recipient: You |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: Merck |
| Recipient: Your Institution |
| Company: Takeda |
| Recipient: Your Institution |
| Company: Pfizer |
| Recipient: Your Institution |
| Company: Daiichi Sankyo |
| Recipient: Your Institution |
| Company: Janssen |
| Recipient: Your Institution |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: AstraZeneca |
| Recipient: Your Institution |
| Company: Amgen |
| Recipient: Your Institution |
| Company: Chugai Pharma |
| Recipient: Your Institution |
| Company: Dizal Pharma |
| Recipient: Your Institution |
| Company: Tempus |
| Recipient: Your Institution |
| Company: nalo therapeutics |
| Recipient: Your Institution |
| Company: Puma Biotechnology |
| Recipient: Your Institution |
| Company: Lilly |
| Recipient: Your Institution |
| Company: Prelude Therapeutics |
| Recipient: Your Institution |
| Company: Tempus |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| No Relationships to Disclose |
|
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| No Relationships to Disclose |
|
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Open Payments Link |
| No Relationships to Disclose |
|
|